STAAR SURGICAL (STAA) Company Report

STAAR Surgical reported Q4 2025 total net sales of $57.8 million and a gross profit margin of 75.7%. Adjusted EBITDA was a loss of $200,000, a significant improvement from a $20.8 million loss in the prior year quarter.
Warren Foust and Deborah Andrews were appointed Interim Co-CEOs effective February 1st, 2026, with a search for a permanent CEO underway.
The company launched EVO+ in China and expanded the age range indication for EVO in the United States to 21-60 years, adding approximately 8 million potential candidates.
After a difficult 2025, STAAR anticipates 2026 to be a year of growth and improving profitability, targeting overall profitability for FY 2026. The company expects to maintain its operating expense run rate generally aligned to the $225 million target.
China's market conditions stabilized in 2025, with in-market EVO ICL demand recovering at mid-single digit rates, and distributor inventory levels returning to contractual levels by late 2025, which is expected to lead to improved net sales for STAAR in 2026 and beyond.

4 days ago

Transcript

STAAR Surgical Reports Q4 2025 Results and Appoints Interim Co-CEOs

STAA

Earnings

CEO Change

Product Launch

Debra Andrews and Warren Foust were appointed Interim Co-CEOs of STAAR Surgical effective February 1st, 2026, and the board has engaged a search firm for a new chief executive officer.
For Q4 2025, STAAR Surgical reported total net sales of $57.8 million, an increase from $49 million in the prior year quarter, with a gross profit margin of 75.7% and an adjusted EBITDA loss of $200,000, significantly improved from a $20.8 million loss in the year-ago quarter.
The company expects 2026 to be a year of growth and improving profitability, targeting overall profitability in FY 2026 due to significant cost reductions in 2025 and anticipated sales increases.
In 2025, China's in-market EVO ICL demand recovered at mid-single digit rates, and STAAR Surgical launched EVO+ in China. The U.S. market saw an expanded age range indication for EVO, adding approximately 8 million more potential candidates.

4 days ago

Transcript

STAAR Surgical Reports Q4 2025 Results, Appoints Interim Co-CEOs, and Outlines 2026 Growth Plan

STAA

Earnings

CEO Change

Guidance Update

STAAR Surgical reported Q4 2025 net sales of $57.8 million, with China net sales contributing $17.5 million.
Warren Foust and Deborah Andrews were appointed Interim Co-CEOs effective February 1st, and a search for a permanent CEO is underway.
Following a challenging 2025, the company anticipates 2026 to be a year of growth, improving profitability, and meaningful progress across its innovation pipeline.
In China, in-market EVO ICL demand recovered at mid-single-digit rates in 2025, and distributor inventory levels reached contractual levels, providing optimism for 2026.
Strategic initiatives include the launch of EVO+ in China, an expanded US age range indication for EVO, and accelerated Swiss manufacturing to support growth and mitigate tariffs.

4 days ago

Transcript

STAAR Surgical Reports Q4 and FY 2025 Results

STAA

Earnings

CEO Change

M&A

STAAR Surgical reported Q4 2025 net sales of $57.8 million, an 18.1% increase year-over-year, and a net loss of $(18.3) million or $(0.37) per share. For the full fiscal year 2025, net sales were $239.4 million, down 23.7% year-over-year, with a net loss of $(80.4) million or $(1.62) per share.
The company appointed Warren Foust and Deborah Andrews as interim co-Chief Executive Officers on February 2, 2026, following the termination of the proposed merger with Alcon in January 2026, allowing a renewed focus on long-term value creation.
In fiscal year 2025, STAAR Surgical implemented significant cost reductions, resulting in a 9.4% reduction in operating expenses (excluding merger and restructuring costs), and made progress in rebalancing distributor inventory in China.
Key product developments include regulatory approval for EVO+ ICL in China in mid-2025 and the FDA expansion of EVO ICL's approved age range in the U.S. to 21-60. The company also repurchased approximately 376,000 shares for $6.5 million under its $30 million share repurchase program.

4 days ago

8-K

STAAR Surgical Announces Leadership Transition and 2026 Outlook

STAA

CEO Change

Guidance Update

M&A

STAAR Surgical transitioned to Interim co-Chief Executive Officers in February 2026, following shareholders overwhelmingly rejecting a proposed merger with Alcon in January 2026.
2025 was a difficult year for STAAR, characterized by macroeconomic headwinds in China, underperforming initiatives, and disruptions from the proposed merger, which impacted revenue growth and profitability. However, the company implemented significant cost reductions and normalized China channel inventory by late 2025.
The company anticipates 2026 to be a much better year, expecting renewed growth, improving profitability, and meaningful progress across its innovation pipeline. Core objectives for 2026 include revenue growth, profit expansion, and innovation acceleration.
Product momentum includes regulatory approval for EVO+ in China in mid-2025, with initial shipments exceeding expectations, and the FDA expanding EVO ICL's approved age range in the U.S. to 21-60.

4 days ago

Press Release

STAAR Surgical Reports Q4 and FY 2025 Results, Appoints Interim Co-CEOs

STAA

Earnings

CEO Change

Demand Weakening

STAAR Surgical reported Q4 2025 net sales of $57.8 million, an 18.1% increase year-over-year, and a net loss of $(18.3) million or $(0.37) per share. For fiscal year 2025, net sales were $239.4 million, a 23.7% decrease year-over-year, with a net loss of $(80.4) million or $(1.62) per share.
The company ended fiscal year 2025 with $187.5 million in cash, cash equivalents, and investments available for sale and repurchased approximately 376,000 shares for $6.5 million.
Net sales excluding China for Q4 2025 decreased by 2.1% to $40.3 million, while for FY 2025, they increased by 6.6% to $161.7 million.
Sales in Q4 2025 were affected by inventory returns in China due to uncertainties regarding a potential acquisition by Alcon, but the company expects modest growth in China net sales in 2026 driven by rising average selling prices and market share gains from the EVO+ ICL launch.
Warren Foust and Deborah Andrews were appointed interim co-Chief Executive Officers on February 2, 2026, and a search for a permanent CEO is in progress.

4 days ago

Press Release

STAAR Surgical Reports Narrower Q4 Net Loss and Revenue Growth

STAA

Earnings

Demand Weakening

Board Change

STAAR Surgical reported a narrower fourth-quarter net loss of $18.3 million ($0.37 per share) on net sales that rose 18.1% to $57.8 million.
For the full fiscal year, the company recorded a net loss of $80.4 million and an Adjusted EBITDA loss of $(6.6) million.
Adjusted EBITDA improved to essentially breakeven in the fourth quarter, compared to a loss of $(20.8) million a year earlier.
Sales growth was primarily driven by China, although reductions in sub-distributor and customer inventory prevented the in-market recovery from fully translating into company sales for the quarter.
The company is undergoing board and leadership transitions and expressed confidence in a clear path toward sustained profitability and growth in 2026.

5 days ago

Morningstar

STAAR Surgical receives expanded FDA age indication for EVO ICL

STAA

Product Launch

New Projects/Investments

The U.S. Food and Drug Administration (FDA) has expanded the age indication for STAAR Surgical's EVO/EVO+ Visian Implantable Collamer Lenses to 21 to 60 years old, up from the previous 21 to 45 years old.
This expansion makes the EVO ICL available to nearly 8 million additional refractive patients in the U.S. and is supported by three-year FDA clinical trial safety data demonstrating a strong safety profile.
The U.S. refractive market is experiencing a notable shift, with laser-based procedures declining nearly 40% over the past three years, while EVO ICL implantations are growing.
EVO ICL is now the most-performed refractive procedure (72%) for U.S. patients with -8.0 diopters and above, indicating a clear shift in treatment patterns for high myopia.

Feb 17, 2026, 9:01 PM

Press Release

STAAR Surgical Company appoints interim co-CEOs

STAA

CEO Change

Management Change

Executive Compensation

STAAR Surgical Company appointed Warren Foust and Deborah Andrews as interim co-Chief Executive Officers, effective February 1, 2026, following the departure of Stephen C. Farrell.
Mr. Foust, previously President and Chief Operating Officer, and Ms. Andrews, Chief Financial Officer, will continue in their current roles while leading the company's day-to-day operations.
A global search for a new Chief Executive Officer has been initiated by a Search Committee.
For their service as interim co-CEOs, both Mr. Foust and Ms. Andrews received an equity award of restricted stock units (RSUs) with a grant date fair value of $375,000 each, vesting on August 1, 2026.

Feb 2, 2026, 12:00 PM

8-K

STAAR Surgical Appoints Interim Co-CEOs

STAA

CEO Change

Management Change

Hiring

STAAR Surgical Company has appointed Warren Foust and Deborah Andrews as interim co-Chief Executive Officers, effective February 1, 2026.
Mr. Foust previously held the role of President and Chief Operating Officer, and Ms. Andrews served as Chief Financial Officer.
The Board of Directors has initiated a global search for a new CEO, considering both internal and external candidates.

Feb 2, 2026, 12:00 PM

Press Release